WO1996028148A3 - Use of a r-nsaid in a protective composition for the treatment of colorectal cancer - Google Patents

Use of a r-nsaid in a protective composition for the treatment of colorectal cancer Download PDF

Info

Publication number
WO1996028148A3
WO1996028148A3 PCT/US1996/003495 US9603495W WO9628148A3 WO 1996028148 A3 WO1996028148 A3 WO 1996028148A3 US 9603495 W US9603495 W US 9603495W WO 9628148 A3 WO9628148 A3 WO 9628148A3
Authority
WO
WIPO (PCT)
Prior art keywords
nsaid
colorectal cancer
composition
treatment
protective composition
Prior art date
Application number
PCT/US1996/003495
Other languages
French (fr)
Other versions
WO1996028148A2 (en
Inventor
William J Wechter
John D Mccracken
Original Assignee
Univ Loma Linda Med
William J Wechter
John D Mccracken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Loma Linda Med, William J Wechter, John D Mccracken filed Critical Univ Loma Linda Med
Priority to EP96911306A priority Critical patent/EP0814796B1/en
Priority to BR9607212-1A priority patent/BR9607212A/en
Priority to AT96911306T priority patent/ATE296097T1/en
Priority to AU54227/96A priority patent/AU713569B2/en
Priority to BR9604881-6A priority patent/BR9604881A/en
Priority to CA002215329A priority patent/CA2215329C/en
Priority to DE69634776T priority patent/DE69634776T2/en
Priority to JP8527818A priority patent/JPH11502199A/en
Priority to DK96911306T priority patent/DK0814796T3/en
Publication of WO1996028148A2 publication Critical patent/WO1996028148A2/en
Publication of WO1996028148A3 publication Critical patent/WO1996028148A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A composition for use in preventing colorectal cancer and other neoplactic diseases includes an enantiomerically stable R-NSAID or a pharmaceutically acceptable salt thereof in an amount effective to elicit a chemoprotective effect. The composition is substantially free of the S-enantiomer of the R-NSAID. Therapeutic use of the composition is accompagnied by reduced adverse side effects.
PCT/US1996/003495 1995-03-13 1996-03-13 Use of a r-nsaid in a protective composition for the treatment of colorectal cancer WO1996028148A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP96911306A EP0814796B1 (en) 1995-03-13 1996-03-13 Use of a r-nsaid in a protective composition for the treatment of colorectal cancer
BR9607212-1A BR9607212A (en) 1995-03-13 1996-03-13 Use of an nsaid-r in a protective composition for the treatment of colon cancer
AT96911306T ATE296097T1 (en) 1995-03-13 1996-03-13 USE OF AN R-NSAID AS A CHEMOPROTECTIVE AGENT TO TREAT COLORECTAL CANCER
AU54227/96A AU713569B2 (en) 1995-03-13 1996-03-13 Use of a r-nsaid in a protective composition for the treatment of colorectal cancer
BR9604881-6A BR9604881A (en) 1995-03-13 1996-03-13 Composition, method of obtaining a colorectal chemoprotective effect with reduced gastrointestinal toxicity and method of treating neoplastic disease with reduced gastrointestinal toxicity
CA002215329A CA2215329C (en) 1995-03-13 1996-03-13 Colorectal chemoprotective composition and method for preventing colorectal cancer
DE69634776T DE69634776T2 (en) 1995-03-13 1996-03-13 USE OF AN R-NSAID AS A CHEMICAL PROTECTION AGENT FOR THE TREATMENT OF COLORECTAL CANCER
JP8527818A JPH11502199A (en) 1995-03-13 1996-03-13 Use of R-NSAIDs in protective compositions for the treatment of colon cancer
DK96911306T DK0814796T3 (en) 1995-03-13 1996-03-13 Use of an R-NSAID in a protective composition for the treatment of colorectal cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US402,797 1995-03-13
US08/402,797 US5955504A (en) 1995-03-13 1995-03-13 Colorectal chemoprotective composition and method of preventing colorectal cancer

Publications (2)

Publication Number Publication Date
WO1996028148A2 WO1996028148A2 (en) 1996-09-19
WO1996028148A3 true WO1996028148A3 (en) 1996-11-14

Family

ID=23593347

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/003495 WO1996028148A2 (en) 1995-03-13 1996-03-13 Use of a r-nsaid in a protective composition for the treatment of colorectal cancer

Country Status (13)

Country Link
US (1) US5955504A (en)
EP (1) EP0814796B1 (en)
JP (1) JPH11502199A (en)
CN (1) CN1183717A (en)
AT (1) ATE296097T1 (en)
AU (1) AU713569B2 (en)
BR (2) BR9607212A (en)
CA (1) CA2215329C (en)
DE (1) DE69634776T2 (en)
DK (1) DK0814796T3 (en)
ES (1) ES2240992T3 (en)
PT (1) PT814796E (en)
WO (1) WO1996028148A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076366B2 (en) 2009-01-15 2011-12-13 Cephalon, Inc. Forms of bendamustine free base

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US6160018A (en) * 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
WO1997048391A2 (en) * 1996-06-21 1997-12-24 Advanced Research And Technology Institute Methods and compositions comprising r-ibuprofen
ES2253810T3 (en) * 1997-03-10 2006-06-01 Loma Linda University Medical Center USE OF R-AINES FOR THE PREVENTION OF ALZHEIMER'S DISEASE.
NZ509376A (en) * 1998-07-09 2003-10-31 Francis A Nardella Indole or carbazole derivatives for the treatment of chronic lyphocytic leukemia
US7105560B1 (en) * 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
US7129262B2 (en) * 1999-07-23 2006-10-31 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US7361680B2 (en) * 1999-07-23 2008-04-22 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7151100B1 (en) 1999-07-23 2006-12-19 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
WO2002076499A2 (en) 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
US7601846B2 (en) * 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
US20030232794A1 (en) * 2001-06-26 2003-12-18 Cottam Howard B. Use of STAT-6 inhibitors as therapeutic agents
US20030027867A1 (en) * 2001-06-29 2003-02-06 Myriad Genetics, Incorporated Use of R-NSAID compounds for anti-HIV treatment
US20030021786A1 (en) * 2001-07-09 2003-01-30 Gevas Philip C. Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
WO2004017967A1 (en) * 2002-08-22 2004-03-04 Cornell Research Foundation, Inc. Multifunctional cox-2 inhibitors
WO2004026116A2 (en) * 2002-09-19 2004-04-01 The Regents Of The University Of California Use of etodoclac to treat hyperplasia
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
US7314886B2 (en) * 2003-10-02 2008-01-01 Cephalon, Inc. Tetrahydropyrano-indole derivatives
EP1730193A2 (en) * 2004-03-29 2006-12-13 Receptor Biologix, Inc. Monoclonal antibodies to gastrin hormone
WO2006032980A1 (en) 2004-09-22 2006-03-30 Receptor Biologix, Inc. Monoclonal antibolies to progastrin
JP2008519047A (en) * 2004-11-05 2008-06-05 セフアロン・インコーポレーテツド Cancer treatment
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
EP1688413A1 (en) * 2005-02-03 2006-08-09 Hikma Pharmaceuticals Co. Ltd. Benzoxazole derivatives for the prophylaxis and treatment of inflammatory bowel diseases
WO2006102439A2 (en) * 2005-03-23 2006-09-28 Florida Atlantic University Treatment or prevention of cancer and precancerous disorders
US8357720B2 (en) * 2005-03-23 2013-01-22 Florida Atlantic University Treatment or prevention of cancer and precancerous disorders
AR072777A1 (en) 2008-03-26 2010-09-22 Cephalon Inc SOLID FORMS OF BENDAMUSTINE CHLORHYDRATE
CN104224703A (en) * 2008-09-25 2014-12-24 赛福伦公司 Liquid Formulations Of Bendamustine
US9125899B1 (en) * 2010-06-17 2015-09-08 Stc.Unm Modulators of GTPases and their use
EP2468270A1 (en) 2010-12-21 2012-06-27 GALENpharma GmbH (R)-2-(3-fluoro-4-phenylphenyl)propionic acid for use in the treatment of skin diseases
RU2678433C2 (en) 2012-05-10 2019-01-29 Пейнреформ Лтд. Depot formulations of hydrophobic active ingredient and methods for preparation thereof
CA3066756A1 (en) 2017-06-15 2018-12-20 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
CN115181105B (en) * 2022-08-26 2024-05-28 长春亿诺科医药科技有限责任公司 Preparation method and application of R-ketorolac

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200198A (en) * 1990-09-12 1993-04-06 Paz Arzneimittel-Entwicklungsgesellschaft Mbh Medicament and its production and use in the treatment of pain, inflammation and fever in man and animals
WO1993016689A1 (en) * 1992-02-28 1993-09-02 Rhone-Poulenc Rorer S.A. Pharmaceutical composition for use as a pain killer and containing (benzoyl-3 phenyl)-2 propionic-(r) acid
US5331000A (en) * 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
US5382591A (en) * 1992-12-17 1995-01-17 Sepracor Inc. Antipyretic and analgesic methods using optically pure R-ketorolac

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1091403A (en) * 1964-01-24 1967-11-15 Boots Pure Drug Co Ltd Therapeutically active phenylalkane derivatives
DE3824353A1 (en) * 1988-07-19 1990-01-25 Paz Arzneimittelentwicklung METHOD FOR SEPARATING MIXED ENANTIOMER ARYLPROPIONIC ACIDS
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
DE4140185C2 (en) * 1991-12-05 1996-02-01 Alfatec Pharma Gmbh Medicament containing a 2-arylpropionic acid derivative in nanosol form and its preparation
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
US6160018A (en) * 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
WO1997048391A2 (en) * 1996-06-21 1997-12-24 Advanced Research And Technology Institute Methods and compositions comprising r-ibuprofen
US7105560B1 (en) * 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200198A (en) * 1990-09-12 1993-04-06 Paz Arzneimittel-Entwicklungsgesellschaft Mbh Medicament and its production and use in the treatment of pain, inflammation and fever in man and animals
WO1993016689A1 (en) * 1992-02-28 1993-09-02 Rhone-Poulenc Rorer S.A. Pharmaceutical composition for use as a pain killer and containing (benzoyl-3 phenyl)-2 propionic-(r) acid
US5331000A (en) * 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
US5382591A (en) * 1992-12-17 1995-01-17 Sepracor Inc. Antipyretic and analgesic methods using optically pure R-ketorolac

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
C.W. HEATH: "Nonsteroidal antiinflammatory drugs and human cancer.", CANCER, vol. 74, no. 10, 1994, pages 2885 - 2888, XP000600922 *
F. JAMAL: "Pharmacokinetics of enatiomers of chiral non-steroidal anti-inflammatory drugs.", EUR. J. DRUG METAB. PHARMAKOKIN., vol. 13, no. 1, 1988, pages 1 - 9, XP000600930 *
M.J. THUN: "Aspirin, NSAIDs, and digestive tract cancers.", CANCER AND METASTASIS REVIEWS, vol. 13, no. 3-4, 1994, pages 269 - 277, XP000600913 *
W.J. WECHTER: "Drug chirality: on the mechanism of R-aryl propionic acid class NSAIDs. Epimerization in humans and the clinical implications for the use of racemates.", J. CLIN. PHARMACOL., vol. 34, no. 11, 1994, pages 1036 - 1042, XP000600923 *
W.J. WECHTER: "Rac-flurbiprofen is more ulcerogenic than its (S)-enantiomer.", CHIRALITY, vol. 5, no. 7, 1993, pages 492 - 494, XP000600914 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076366B2 (en) 2009-01-15 2011-12-13 Cephalon, Inc. Forms of bendamustine free base

Also Published As

Publication number Publication date
DE69634776T2 (en) 2006-05-11
WO1996028148A2 (en) 1996-09-19
JPH11502199A (en) 1999-02-23
EP0814796B1 (en) 2005-05-25
CA2215329C (en) 2007-09-04
CA2215329A1 (en) 1996-09-19
AU713569B2 (en) 1999-12-02
DK0814796T3 (en) 2005-09-19
EP0814796A2 (en) 1998-01-07
ATE296097T1 (en) 2005-06-15
US5955504A (en) 1999-09-21
ES2240992T3 (en) 2005-10-16
AU5422796A (en) 1996-10-02
BR9607212A (en) 1999-11-30
PT814796E (en) 2005-08-31
CN1183717A (en) 1998-06-03
BR9604881A (en) 1999-11-30
DE69634776D1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
WO1996028148A3 (en) Use of a r-nsaid in a protective composition for the treatment of colorectal cancer
NZ303372A (en) Use of (s)-oxybutynin and (s)-desethyloxybutynin to treat urinary incontinence
AP1529A (en) Therapeutic formulation for administering tolterodine with controlled release.
CA2370030A1 (en) Sodium channel blocker compositions and the use thereof
RO116342B1 (en) Oral liquid pharmaceutical composition
MW390A1 (en) Antiviral or antibacterial compound and method of use
IL120317A (en) Ciprofloxacin-hydrocortisone suspension
CA2214097A1 (en) Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx
AU5876596A (en) Oral dosage and method for treating painful conditions of th e oral cavity
AU3632497A (en) Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
EP1022025A3 (en) Method and compositions for treating emesis nausea and other disorders using optically pure R(+) ondansetron
CA2151724A1 (en) Antipyretic and Analgesic Methods and Compositions Containing Optically Pure R-Ketorolac
PT668763E (en) USE OF FENSERIN FOR THE PREPARATION OF MEDICINES TO TREAT DISEASES OF KNOWLEDGE
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
EP1310256A3 (en) Use of prostaglandin A or its derivatives for the treatment of psoriasis
CA2251966A1 (en) Transdermally administered dextromethorphan as antitussive agent
ES2160643T3 (en) COMPOSITIONS CONTAINING G-CSF AND PROTEIN OF UNION TO TNF.
CA2202397A1 (en) Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
CA2283255A1 (en) Use of r-nsaid's for the prevention of alzheimer's disease
AU6612596A (en) Therapeutic use of 1-amino-3-(n,n-dimethylamino)-propyliden-,1-bisphosphonic acid and its salts
EP1304108A3 (en) Anti-arrhythmic composition and methods of treatment
CA2289017A1 (en) The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
IL103799A (en) Fish production

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96192538.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 1996 527818

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2215329

Country of ref document: CA

Ref document number: 2215329

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1996911306

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996911306

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1996911306

Country of ref document: EP